Nancy Cross

792 total citations
20 papers, 421 citations indexed

About

Nancy Cross is a scholar working on Immunology, Pathology and Forensic Medicine and Dermatology. According to data from OpenAlex, Nancy Cross has authored 20 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 8 papers in Pathology and Forensic Medicine and 4 papers in Dermatology. Recurrent topics in Nancy Cross's work include Psoriasis: Treatment and Pathogenesis (17 papers), Autoimmune Bullous Skin Diseases (8 papers) and Dermatology and Skin Diseases (4 papers). Nancy Cross is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (17 papers), Autoimmune Bullous Skin Diseases (8 papers) and Dermatology and Skin Diseases (4 papers). Nancy Cross collaborates with scholars based in United States, United Kingdom and Belgium. Nancy Cross's co-authors include Andrew Blauvelt, Christopher L. Cioffi, Kim Papp, Luke Peterson, Joseph F. Merola, C.E.M. Griffiths, Alice B. Gottlieb, Richard B. Warren, Richard G. Langley and Kristian Reich and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Nancy Cross

18 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nancy Cross United States 6 367 209 85 79 70 20 421
Jolanta Węgłowska Poland 6 336 0.9× 152 0.7× 77 0.9× 16 0.2× 20 0.3× 16 437
Katherine Armour Australia 8 165 0.4× 99 0.5× 23 0.3× 14 0.2× 36 0.5× 12 267
Nicole Selenko-Gebauer Austria 6 265 0.7× 41 0.2× 22 0.3× 17 0.2× 54 0.8× 7 358
Gustavo Añez Sturchio Spain 7 53 0.1× 34 0.2× 80 0.9× 12 0.2× 12 0.2× 8 199
Guifen Shen China 8 46 0.1× 49 0.2× 48 0.6× 17 0.2× 18 0.3× 15 280
Youngdoe Kim South Korea 9 148 0.4× 24 0.1× 43 0.5× 9 0.1× 5 0.1× 23 226
Stanton K. Wesson United States 9 29 0.1× 72 0.3× 53 0.6× 10 0.1× 59 0.8× 20 257
Tejaswi Mudigonda United States 8 91 0.2× 135 0.6× 5 0.1× 10 0.1× 17 0.2× 12 285
Anurag Bhalla Canada 9 110 0.3× 12 0.1× 15 0.2× 247 3.1× 5 0.1× 17 350
H Kolb Germany 5 138 0.4× 8 0.0× 22 0.3× 17 0.2× 7 0.1× 8 292

Countries citing papers authored by Nancy Cross

Since Specialization
Citations

This map shows the geographic impact of Nancy Cross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Cross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Cross more than expected).

Fields of papers citing papers by Nancy Cross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Cross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Cross. The network helps show where Nancy Cross may publish in the future.

Co-authorship network of co-authors of Nancy Cross

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Cross. A scholar is included among the top collaborators of Nancy Cross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Cross. Nancy Cross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Langley, Richard G., Mark Lebwohl, Bruce Strober, et al.. (2025). Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. Journal of the American Academy of Dermatology. 93(3). 644–653. 1 indexed citations
2.
Merola, Joseph F., Alice B. Gottlieb, Andreas Pinter, et al.. (2024). Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials. Dermatology and Therapy. 14(12). 3291–3306. 2 indexed citations
3.
Youn, Sang Woong, Seong Jin Jo, Chul Jong Park, et al.. (2024). Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo‐controlled, double‐blinded study. The Journal of Dermatology. 51(11). 1392–1403.
4.
Merola, Joseph F., Curdin Conrad, Jo Lambert, et al.. (2024). Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine. 8(1). s304–s304. 1 indexed citations
5.
Lebwohl, Mark, Joseph F. Merola, Bruce Strober, et al.. (2024). Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. Journal of the American Academy of Dermatology. 91(2). 281–289. 2 indexed citations
6.
Thaçi, Diamant, Ronald Vender, Curdin Conrad, et al.. (2022). Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension. SKIN The Journal of Cutaneous Medicine. 6(6). s68–s68. 1 indexed citations
7.
Gordon, Kenneth B., Richard G. Langley, Richard B. Warren, et al.. (2022). Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology. 158(7). 735–735. 36 indexed citations
8.
Lebwohl, Mark, April W. Armstrong, Joseph F. Merola, et al.. (2022). Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials. SKIN The Journal of Cutaneous Medicine. 6(6). s64–s64. 1 indexed citations
9.
Blauvelt, Andrew, Jashin J. Wu, Kristian Reich, et al.. (2021). 27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial. Journal of the American Academy of Dermatology. 85(3). AB139–AB139. 6 indexed citations
10.
Warren, Richard B., Andrew Blauvelt, Jerry Bagel, et al.. (2021). Bimekizumab versus Adalimumab in Plaque Psoriasis. New England Journal of Medicine. 385(2). 130–141. 139 indexed citations
11.
12.
Warren, Richard B., Andrew Blauvelt, Jerry Bagel, et al.. (2021). Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE). SKIN The Journal of Cutaneous Medicine. 5(1). s15–s15. 2 indexed citations
13.
Blauvelt, Andrew, Kim Papp, Joseph F. Merola, et al.. (2020). Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. Journal of the American Academy of Dermatology. 83(5). 1367–1374. 50 indexed citations
14.
Blauvelt, Andrew, Joseph F. Merola, Kim Papp, et al.. (2020). 14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2). Journal of the American Academy of Dermatology. 83(6). AB16–AB16. 2 indexed citations
15.
16.
Blauvelt, Andrew, Kim Papp, Joseph F. Merola, et al.. (2019). AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY. Annals of the Rheumatic Diseases. 78. 1834–1834. 2 indexed citations
17.
Papp, Kim, Joseph F. Merola, Alice B. Gottlieb, et al.. (2018). Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of Dermatology. 79(2). 277–286.e10. 157 indexed citations
18.
Cross, Nancy, J. A. Smerdon, V.R. Dhanak, et al.. (2011). XPS study of adsorption and desorption of a Bi thin film on the five-fold icosahedral Al-Pd-Mn surface. The Philosophical Magazine A Journal of Theoretical Experimental and Applied Physics. 91(19-21). 2889–2893. 4 indexed citations
19.
Smerdon, J. A., Nancy Cross, V.R. Dhanak, et al.. (2010). Structure and reactivity of Bi allotropes on the fivefold icosahedral Al–Pd–Mn quasicrystal surface. Journal of Physics Condensed Matter. 22(34). 345002–345002. 12 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jolanta Węgłowska Breakdown of academic impact, for papers by Katherine Armour Breakdown of academic impact, for papers by Nicole Selenko-Gebauer Breakdown of academic impact, for papers by Gustavo Añez Sturchio Breakdown of academic impact, for papers by Guifen Shen Breakdown of academic impact, for papers by Youngdoe Kim Breakdown of academic impact, for papers by Stanton K. Wesson Breakdown of academic impact, for papers by Tejaswi Mudigonda Breakdown of academic impact, for papers by Anurag Bhalla Breakdown of academic impact, for papers by H Kolb
Rankless by CCL
2026